Additionally, CD49d expression on T lymphocytes can be used as a biomarker of disease progression in DMD (both in humans and in dystrophic dogs), including the stratification of patients before various clinical trials for other therapeutic strategies. Here, ITGA4 is linked to Duchenne muscular dystrophy.